Please try another search
For the nine months ended 30 September 2017, Dimension Therapeutics Inc revenues increased 70% to $12.5M. Net loss increased 19% to $42.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Interest expense increase of 34% to $219K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.44 to -$1.71.
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Revenue | 4.48 | 4.37 | 3.62 | 4.13 |
Gross Profit | ||||
Operating Income | -16.97 | -12.33 | -13.53 | -13.07 |
Net Income | -16.95 | -12.31 | -13.49 | -13.03 |
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Assets | 50.12 | 64.21 | 78.23 | 93.86 |
Total Liabilities | 29.77 | 28.14 | 30.74 | 33.92 |
Total Equity | 20.35 | 36.07 | 47.49 | 59.94 |
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -42.87 | -29.5 | -18.22 | -47.64 |
Cash From Investing Activities | 28.5 | 25.23 | 12.58 | -54.31 |
Cash From Financing Activities | -1.32 | -0.9 | -0.55 | 5.14 |
Net Change in Cash | -15.69 | -5.17 | -6.2 | -96.81 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review